作者
Joseph Grudzinski, Ian Marsh, Benjamin Titz, Justin Jeffery, Marc Longino, Kevin Kozak, Kristofer Lange, Jason Larrabee, Ashley Weichmann, Amy Moser, Bryan Bednarz
发表日期
2018/4/1
期刊
Cancer Biotherapy & Radiopharmaceuticals
卷号
33
期号
3
页码范围
87-95
出版商
Mary Ann Liebert, Inc.
简介
Purpose: Auger electrons emitted by radioisotopes such as 125I have a high linear energy transfer and short mean-free path in tissue (<10 μm), making them suitable for treating micrometastases while sparing normal tissues. The authors developed and subsequently investigated a cancer cell-selective small molecule phospholipid ether analog to deliver 125I to triple-negative breast cancer (TNBC) cells in vivo.
Methods: A Current Good Manufacturing Practice (cGMP) method to radiolabel 125I-CLR1404 (CLR 125) with >95% radiochemical purity was established. To estimate CLR 125 in vivo dosimetry and identify dose-limiting organs, the biodistribution of the analog compound 124I-CLR1404 (CLR 124) was investigated using micro-positron emission tomography (PET)/computed tomography (CT) in conjunction with a Monte Carlo dosimetry platform to estimate CLR 125 dosimetry. In vivo antitumor efficacy was …
引用总数
201920202021202220232024214371
学术搜索中的文章
J Grudzinski, I Marsh, B Titz, J Jeffery, M Longino… - Cancer Biotherapy & Radiopharmaceuticals, 2018